Repeat TURBT Before RC Does Not Improve Bladder Cancer Outcomes
Study results suggest that tumor debulking does not provide benefit patients undergoing radical cystectomy.
Study results suggest that tumor debulking does not provide benefit patients undergoing radical cystectomy.
In a study, acute kidney injury and acute kidney disease developed in 51.4% and 37.5% of patients who underwent radical cystectomy for muscle-invasive bladder cancer.
A 2-dose regimen effectively delivers mitomycin C to the bladder tissue before TURBT, investigators reported.
Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.
Of 19 patients with high-risk NMIBC treated with local docetaxel, 14 had prior BCG exposure.
MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC.
Investigators hypothesize that patients presented later to their health care providers during the first year of the pandemic.
In a small retrospective pilot study, the checkpoint inhibitor tislelizumab added to gemcitabine/cisplatin improved progression-free survival compared with gemcitabine/cisplatin alone among patients with locally advanced or metastatic bladder cancer.
A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
Authors say Gem/Doce warrants further study for the treatment of BCG-naive high-risk non-muscle-invasive bladder cancer